JP2021523126A5 - - Google Patents

Info

Publication number
JP2021523126A5
JP2021523126A5 JP2020561795A JP2020561795A JP2021523126A5 JP 2021523126 A5 JP2021523126 A5 JP 2021523126A5 JP 2020561795 A JP2020561795 A JP 2020561795A JP 2020561795 A JP2020561795 A JP 2020561795A JP 2021523126 A5 JP2021523126 A5 JP 2021523126A5
Authority
JP
Japan
Prior art keywords
months
composition according
accumulated
pathological tau
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523126A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030184 external-priority patent/WO2019213245A1/en
Publication of JP2021523126A publication Critical patent/JP2021523126A/ja
Publication of JP2021523126A5 publication Critical patent/JP2021523126A5/ja
Pending legal-status Critical Current

Links

JP2020561795A 2018-05-03 2019-05-01 蓄積した病理学的Tauタンパク質を低減する方法 Pending JP2021523126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666459P 2018-05-03 2018-05-03
US62/666,459 2018-05-03
PCT/US2019/030184 WO2019213245A1 (en) 2018-05-03 2019-05-01 Methods for reducing accumulated pathologic tau protein

Publications (2)

Publication Number Publication Date
JP2021523126A JP2021523126A (ja) 2021-09-02
JP2021523126A5 true JP2021523126A5 (cg-RX-API-DMAC7.html) 2022-05-10

Family

ID=66530499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561795A Pending JP2021523126A (ja) 2018-05-03 2019-05-01 蓄積した病理学的Tauタンパク質を低減する方法

Country Status (4)

Country Link
US (1) US20210137861A1 (cg-RX-API-DMAC7.html)
EP (1) EP3787750A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021523126A (cg-RX-API-DMAC7.html)
WO (1) WO2019213245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076330B2 (en) 2018-04-27 2024-09-03 The Regents Of The University Of California Inhibition of lipofuscin aggregation by molecular tweezers
JP2021522282A (ja) 2018-04-27 2021-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California リソソーム蓄積障害の治療
EP4110315A4 (en) * 2020-02-24 2024-03-06 Oblato, Inc. Compositions and methods for treating cancer and tumor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335007T1 (de) * 1993-12-21 2006-08-15 Innogenetics Nv Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
MXPA05004828A (es) * 2002-11-07 2006-01-27 Applied Neurosolutions Inc Metodos para predecir si sujetos con deterioro cognoscitivo leve (mci) desarrollaran o no la enfermedad de alzheimer.
CA2772097C (en) * 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
WO2012106654A1 (en) * 2011-02-04 2012-08-09 Hough Ear Institute Methods for treating brain injury
US20140249180A1 (en) * 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
WO2017048778A1 (en) * 2015-09-18 2017-03-23 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
US10576125B2 (en) * 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis

Similar Documents

Publication Publication Date Title
Murphy et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease
Roberts et al. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis
JP2019537582A5 (cg-RX-API-DMAC7.html)
Bates et al. Ototoxicity induced by gentamicin and furosemide
Kornblut et al. Ear disease in patients with Wegener's granulomatosis
JP2011527339A5 (cg-RX-API-DMAC7.html)
Petejova et al. Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients.
JP2019524834A5 (cg-RX-API-DMAC7.html)
JP2025060686A5 (cg-RX-API-DMAC7.html)
JP2018522938A (ja) 難聴の処置のためのセトロンファミリーのカルシニューリン阻害剤
US12121513B2 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
JP2015523346A5 (cg-RX-API-DMAC7.html)
DOP2021000015A (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
JP2018505218A5 (cg-RX-API-DMAC7.html)
JP2020504154A5 (cg-RX-API-DMAC7.html)
US20250000795A1 (en) Treatment of sepsis and septic shock
JP2020527138A5 (cg-RX-API-DMAC7.html)
US20210137861A1 (en) Methods for reducing accumulated pathologic tau protein
CN117651556A (zh) 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案
RU2220730C2 (ru) Способ лечения герпетического стоматита
JP2023521161A5 (cg-RX-API-DMAC7.html)
JP2024526880A5 (cg-RX-API-DMAC7.html)
JP2026501711A (ja) 聴覚障害の治療のための併用療法
IL313067A (en) Methods of treating neurological disorders
Akingbola et al. Therapeutic plasma exchange in the management of myasthenia crisis in a resource poor setting